Новый блокатор кальциевых каналов группыдигидропиридина лерканидипин

1. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension, in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–13.
2. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England. Hypertens. 1998; 16: 747–52.
3. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the "rule of hikes” still valid? Hum Hypertens. 1997; 11: 213–23.
4. The global burden of disease: a comprehensive assessment of mortality and disability from all diseases, injuries, and risk factors in 1990 and projected to 2020. Eds. CJL.Murray, AD.Lopez. http://wmv.who.int/msa/nmh/ ems/dalys/intro.hrm#intro. Accessed July 31, 2001.
5. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–8.
6. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. Arch Intern Med 1993; 153: 598–615.
7. Staessen JA, Fagard R, Thijs I et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64.
8. Yusuf S, Sleight P, Pogue J et al. for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converring-enzyme inhibitor, ramipril, on cardiovascular events in. high-risk patients. N Engl J Med 2000; 342: 145–53.
9. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pres-sure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–62.
10. UK Prospecrive Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. 1998; 317: 703–13.
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captnpril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20.
12. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–46.
13. Guidelines Subcommittee. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–83.
14. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension, 2000; 35: 1021–4.
15. Dusing R, Weisscr B, Mcngden T et al. Changes in antihypertensive therapy – the role of adverse effects and compliance. Stood Press 1998; 7: 313–5.
16. Aranda P, Tamargo J, Aranda FJ et al. Use and adverse reactions of antihypertensive drugs in Spain. Blood Pros l997; 1 (Suppl): 11–6.
17. Caro JJ, Salas M, Speckman JL et al. Persistence with treatment for hypertension in actual practice. SMAJ 1999; 160: 31–7.
18. Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep 2000; 2: 515–24.
19. Garfield FB, Caro JJ. Compliance and hypertension. Curr Hypertens Rep 1999; 1: 502–56.
20. Hill MN, Bone LR, Kim MT et al. Barriers to hypertension care and control in young urban black men. Am J Hypertens 1999; 12: 951–8.
21. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 43–9.
22. Burke LE, Dunbar-Jacob JM, Hill MN. Compliance with cardiovascular disease prevention strategies: a review of the research. Ann Behav Med 1997; 19: 239–63.
23. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996; 156: 1969–78.
24. Sheinfeld GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens 1999; 12: 80S–85.
25. Epstein M. Calcium antagonists in the management of hypertension. In: Epstein M (ed). Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley _Belfus, 1998: 155–76.
26. Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Drugs 1999; 58: 579–87.
27. Corry DB, Tuck ML. Insulin and glucoregulatory hormones: implications for antihypertensive therapy. Ed. M.Epstein. Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley & Belfus, 1998: 215–42.
28. Goldberg RB, Florez H. Effects of calcium antagonists on lipids. In: Epstein M (ed). Calcium Antagonists™ Clinical Medicine. 2nd ed. Philadelphia: Hanley& Belfus, 1998: 359–68.
29. Kizer IR, Kimmel SE. Epidemiologic review of calcium channel blocker drugs. Arch Intern Med 2001; 161: 1145–58.
30. Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000; 160: 2447–2452.
31. Specchia G, Saccaggi SP, Ghezzi C. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. CURR TherRes 2001; 62: 3–15.
32. van der Lee R, Pfaffendorf M, ran Zwieten PA. The differential time course of the vasodilator effects of various 1,4-dihydropyridines in isolated human small arteries are correlated to their lipophilicity. J Hypertens 2000; 18: 1677–82.
33. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: short plasma half-life, long duration of action. J Cardiovasc Pharmacol 1997; 29 (Supp. 1 ): S19–24.
34. Ahernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341: 1447–57.
35. Herbette LG, Vecchiarelli M, Sartani A et al. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press 1998; 7 (Suppl 2): 10–7.
36. Gasser R, Koppel H, Klein W. Lercanidipine, a new third generation Ca-antagonist in the treatment of hypertension. J Clin Basic Cardiol 1999; 2: 169–74.
37. Leonardi A, Poggesi E, Tiiddei C et al. In vitro calcium antagonist activity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997; 29 (Suppl 1): S10–S18.
38. Ninci MA, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997; 29 (Suppl 2): S40–44.
39.Ambrosioni E, Circo A. Activity of lercanidipine administered in single and repeated doses once daily as monitored over 24 hours in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl 2): S16–20.
40. Leonardi A, Motta G, Pennini R et al. Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6-dimcthyl-l,4-dihydropyridine-3,5-dicarbosylic acids with antihypertensive activity. Eur J Med Chen 1998; 33: 399–420.
41. Farina P, Targa G, Leoni B et al. Pharmacokinetics of lercanidipine in animals. II. Distribution to and elimination from organs and tissues after administration of [14C]-Iercanidipinc to rats and dogs. Whole-body autoradiography, biliary excretion and enterohepatic circulation and biotransformation in rats. Cardiovasc Pharmacol 1997; 29 (Suppl 1): S97–108.
42. Mason RP, Moisy DM, Shajenko L. Cholesterol alters tire binding of CA2+ channel blockers to the membrane lipid bilayer. Mol Pharmacol 1992; 41: 315–21.
43. Barchielli M, Dolfini E, Farina P et al. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol 1997; 29 (Suppl 2): S1–15.
44. Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Exp Opin Invest Drugs 1999; 8: 1043–62.
45. Omboni S, Zanchetti A, for the Multicenter Study Investigators. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998; 16: 1831–8.
46. Circo A. Active dose findings for lercanidipine in a double-blind, placebo-controlled design in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl 2): S21–25.
47. Patema S, Licata A, Amone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl 2): S50–53.
48. De Giorgio LA, Orlandini F, Malasoma P et al. Double-blind crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Ther Res 1999; 60: 511–20.
49. Morisco C, Trimarco B. Efficacy and tolerability of Iercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double-blind controlled study. Cardiavasc Pharmacol 1997; 29 (Suppl 2): S26–30.
50. Barbagallo Sangiorgi G, Piitignano E et al. Efficacy and tolerability of Iercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J Cardiavasc Pharmacol 1997; 29 (Suppl 2): S36–39.
51. Policichio D, Magliocca R, Malliani A. Efficacy and tolerability of Iercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiavasc Pharmacol 1997; 29 (Suppl 2): S31–35.
52. Rengo F, Romis L. Activity of Iercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension. J Cardiovnsc Pharmacol 1997; 29 (Suppl 2): S54–58.
53. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of Iercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12: 375–9.
54. Nutarbartolo A, Rengo F, Scafidi V et al. Long-term effects of Iercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. Curr Ther Res 1999; 60: 228–36.
55. Fogiri R, Malamani G.D, Zoppi A et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. Curr Ther Res 2000; 61: 850–62.
56. Fogari R, Mugellini A, Corradi L et al. Efficacy of Iercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract]. J Hypertens, 2000; 18 (Suppl 2): S65.
57. Sanchez Gomez A, Sayans Gomez R, Alvarez JL et al. Left ventricular hypertrophy regression after and hypertensive treatment with Iercanidipine vs enalapril [abstract], Presented at the 5th National Meeting of the Spanish Society of Hypertension; March 7–10, 2000; Madrid, Spain.
58. Aranda P, Aranda FT, Bianchi JL et al. Therapeutic efficacy and tolerability of Iercanidipine versus candesartan, alone or in combination, in mild-moderate essential hypertensives [abstract]. J Hypertens, 2000; 18 (Suppl 2): S152.
59. Sironi G, Montagna E, Greto L et al. Haemodynamic effects of Iercanidipine in anaesthetized open-chest dogs. Arzneim Forsch Drug Res 1996; 46: 256–61.
60. Testa R, Rimoldi O, Sironi G et al. Hemodynamic effects and power spectral analysis of heart rate and arterial pressure variabilities induced by Icrcanidipine and its enantiomers in conscious dogs. Cardiavasc Pharmacol 1997; 29 (Suppl 1) 378–585.
61. Bianchi G, Passoni A, Griffini PL. Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharm Res 1989; 21: 193–200.
62. Corsini A, Bonfatti M, Quarato P et al. Effect of the new calcium antagonist Iercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol 1996; 28: 687–94.
63. Corsini A, Accomazzo MR, Canavesi M et al. The new calcium antagonist Iercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press 1998; 7 (Suppl 2): 18–22.
64. Soma MR, Natali M, Donetti E et al. Effect of Iercanidipine and its R-enantlomer on atherosclerotic lesions induced in hyperholesterolemic rabbits. Br J Pharmacol 1998; 1 (25): 1471–76.
65. Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775–9.
66. Sabbatini M, Vitaioli L, Baldoni E et al. Nephroprotectivc effect of treatment with calcium channel blockers in spontaneously hypertensive rats, J Pharm Exp Ther 2000; 294: 948–54.
67. Sabbatini M, Tomassoni D, Amenta P. Influence of treatment with Ca2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Age Dep 2001; 122: 795–809.
68. Cavallini A, Terzi G. Effects of antihypertensive therapy with Iercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double-blind pilot study. Curr Ther Res 2000; 61: 477–87.
69. Cesarone MR, Ineandela L, Ledda A et al. Pressure and microcirculatory effects of treatment with Iercanidipine in hypertensive patients and in vascular patients with hypertension. Angiology 2000, 51: S53–63.
70. Testa R, Leonardi A, Tajana A et al. Lercanidipine (Rec 15/2375): a novel 1,4-dihydropyridiiie calcium antagonist for hypertension. Cardiavasc Drug Rev 1999; 15: 187–219.
71. Borghi C, Prandin MG, Dormi A. The use of Iercanidipine can improve the individual tolerability to dihydropyridine calcium blockers in hypertensive patients [abstract]. J Hypertens 2000; 18 (Suppl 2): S155.
72. Acanfora D, Gheorgiade M, Rotiroti D et al. Acute dose-response, double-blind, placebo-controlled pilot study of Iercanidipine in patients with angina pectoris. Curr Ther Res 2000; 61: 255–65.
73. Leenen FH. Dihydropyridine calcium antagonists and sympathetic activity: relevance to cardiovascular morbidity and mortality. In: Epstein M (ed). Calcium Antagonists in Clinical Medicine. Philadelphia: Hanlev & Belfus, 1998: 527–52.
74. Epstein M. Safety of calcium antagonists as antihypertensive agents: an update. In: Epstein M (ed). Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley & Belfus, 1998; 553–71.
75. Cafiero M, Giasi M. Long-term (12-month) treatment with Iercanidipine in patients with mild to moderate hypertension. Cardiavasc Pharmacol 1997; 29 (Suppl 2): S45–49.
76. Hedner T, Everts B, Krazei H et al. Enhanced blood pressure lowering effect in hypertensive patients on combined sildenalil and Iercanidipine treatment [abstract]. J Hypertens 2000;18; (Suppl 2): S165.
77. McGlellan KJ, Jarvis B. Lercanidipme: a review of its use in hypertension. Drugs 2000; 60: 1123–40.
78. Conlin PR, Williams OH. Use of calcium channel blockers in hypertension. Eds. RW.Schrier, JD.Baxter, VJ.Dzau, et al. Advances in Internal Medicine. St, Louis, MO: Mosby-Year Bonk Inc, 1998; 43: 533–662.

M.Epstein